Across these trials, SSRIs (citalopram, paroxetine, sertraline, and fluoxetine) 47, 51, 52, a norepinephrine‐dopamine reuptake inhibitor (bupropion) 51, 52, a serotonin–norepinephrine reuptake inhibitor (venlafaxine) 52, a reversible inhibitor of monoamine oxidase A (moclobemide) 51, a non‐selective irreversible monoamine oxidase inhibitor (phenelzine) 52, and a norepinephrine reuptake blocker (desipramine) 47 were used in relevant clinical doses over 8–20 weeks to treat a total number of 469 patients suffering major depression. The gene discussed is MAOA; the disease is major depressive disorder.